Reimbursement Is More Than Passing Thought For Spine Firm In FDA Trials
Non-fusion spinal implant maker Paradigm Spine decided to spend 15%-20% more than needed to satisfy FDA's data requirements in an ongoing pivotal trial for what the company hopes will be its first product on the U.S. market
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
